TY - JOUR
T1 - Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators
T2 - two randomised clinical trials
AU - Fabbri, Leonardo M
AU - Calverley, Peter M A
AU - Izquierdo-Alonso, José Luis
AU - Bundschuh, Daniela S
AU - Brose, Manja
AU - Martinez, Fernando J
AU - Rabe, Klaus F
AU - M2-127 and M2-128 study groups
AU - Macnee, Bill
PY - 2009
Y1 - 2009
N2 - Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated.
AB - Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the phosphodiesterase-4 inhibitor roflumilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated.
U2 - 10.1016/S0140-6736(09)61252-6
DO - 10.1016/S0140-6736(09)61252-6
M3 - Article
C2 - 19716961
SN - 1474-547X
VL - 374
SP - 695
EP - 703
JO - The Lancet
JF - The Lancet
IS - 9691
ER -